Windtree Therapeutics Inc (WINT)

$0.60 +0.01 (1.35%)
Market Cap 2.17M
Revenue (ttm) 0.00
Net Income (ttm) -1.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.05
Volume 2,294,600
Avg Vol 2,696,306
Day's Range N/A - N/A
Shares Out 3.66M
Stochastic %K 14%
Beta 0.77
Analysts Hold
Price Target $4.00

Company Profile

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in a Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in a Phase 2b clinical trial to treat respiratory distress syndrome in premature in...

Industry: Biotechnology
Sector: Healthcare
Phone: 215 488 9300
Address:
2600 Kelly Road, Suite 100, Warrington, United States
DDavidson777
DDavidson777 Jun. 16 at 10:32 PM
$WINT just a matter of time folks… 📈📈📈💚 Dont miss out on another banger… Crazy calls in past months or so and nearly another $1,000,000 locked in. Follow for more
0 · Reply
WSSHARKS
WSSHARKS Jun. 16 at 9:04 PM
$WINT If good news can't lift it, imagine what no news or bad news will do — straight to the incinerator
0 · Reply
Joe_088
Joe_088 Jun. 16 at 8:09 PM
$WINT
0 · Reply
abimbolajosh
abimbolajosh Jun. 16 at 7:09 PM
$WINT you are a pumper lol You’ve got to prove it
1 · Reply
kunnskap
kunnskap Jun. 16 at 7:03 PM
$WINT
0 · Reply
kunnskap
kunnskap Jun. 16 at 7:00 PM
$WINT
0 · Reply
Joe_088
Joe_088 Jun. 16 at 6:57 PM
$WINT ah or before close🌋
0 · Reply
GravyTrain1
GravyTrain1 Jun. 16 at 6:53 PM
$WINT what is this bs!
0 · Reply
GravyTrain1
GravyTrain1 Jun. 16 at 6:41 PM
$WINT
0 · Reply
Luke83
Luke83 Jun. 16 at 6:39 PM
$FOXO $BPT $WINT $MULN on watch
0 · Reply
Latest News on WINT
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

May 22, 2025, 8:16 AM EDT - 25 days ago

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

May 12, 2025, 8:00 AM EDT - 5 weeks ago

Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

May 6, 2025, 8:18 AM EDT - 5 weeks ago

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

Mar 26, 2025, 8:47 AM EDT - 2 months ago

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Mar 24, 2025, 8:30 AM EDT - 3 months ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

ADTX

Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

Mar 24, 2025, 8:00 AM EDT - 3 months ago

Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

Mar 20, 2025, 8:00 AM EDT - 3 months ago

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline

Jan 15, 2025, 8:00 AM EST - 5 months ago

Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline

Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

Jan 13, 2025, 8:00 AM EST - 5 months ago

Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

Dec 9, 2024, 8:00 AM EST - 6 months ago

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

Dec 4, 2024, 8:00 AM EST - 6 months ago

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

Nov 27, 2024, 4:05 PM EST - 7 months ago

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World

Oct 23, 2024, 8:00 AM EDT - 8 months ago

Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan

Oct 17, 2024, 8:15 AM EDT - 8 months ago

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Sep 30, 2024, 8:15 AM EDT - 9 months ago

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

Sep 26, 2024, 4:05 PM EDT - 9 months ago

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Sep 25, 2024, 8:15 AM EDT - 9 months ago

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

Aug 20, 2024, 4:05 PM EDT - 10 months ago

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

Windtree Announces New Additions and Changes to Its Board of Directors

Aug 14, 2024, 4:05 PM EDT - 10 months ago

Windtree Announces New Additions and Changes to Its Board of Directors

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

Jul 25, 2024, 8:00 AM EDT - 11 months ago

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

Windtree Therapeutics Regains Compliance with Nasdaq

May 7, 2024, 8:00 AM EDT - 1 year ago

Windtree Therapeutics Regains Compliance with Nasdaq

What made Windtree Therapeutics stock tank 20% on Monday?

Apr 22, 2024, 11:06 AM EDT - 1 year ago

What made Windtree Therapeutics stock tank 20% on Monday?

Windtree Therapeutics Announces Reverse Stock Split

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Windtree Therapeutics Announces Reverse Stock Split

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

Apr 8, 2024, 4:48 PM EDT - 1 year ago

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

Feb 1, 2024, 8:00 AM EST - 1 year ago

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

Jan 31, 2024, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

Jan 26, 2024, 9:20 AM EST - 1 year ago

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

Jan 25, 2024, 8:30 AM EST - 1 year ago

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

Jan 18, 2024, 9:00 AM EST - 1 year ago

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

Windtree Therapeutics Announces License Agreement with Lee's Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

Jan 17, 2024, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces License Agreement with Lee's Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

Jan 2, 2024, 4:05 PM EST - 1 year ago

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024

Dec 19, 2023, 9:30 AM EST - 1 year ago

Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Dec 18, 2023, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent

Nov 16, 2023, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent

Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates

Nov 9, 2023, 4:15 PM EST - 1 year ago

Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates

Windtree to Present at the Sidoti Micro Cap Conference on November 16th

Nov 8, 2023, 8:00 AM EST - 1 year ago

Windtree to Present at the Sidoti Micro Cap Conference on November 16th

Windtree to Present at the ThinkEquity Conference on October 19th in New York City

Oct 12, 2023, 7:30 AM EDT - 1 year ago

Windtree to Present at the ThinkEquity Conference on October 19th in New York City

Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th

Oct 10, 2023, 7:30 AM EDT - 1 year ago

Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th

Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th

Oct 3, 2023, 8:00 AM EDT - 1 year ago

Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th

Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office

Aug 23, 2023, 8:00 AM EDT - 1 year ago

Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office

Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market

Aug 16, 2023, 9:00 AM EDT - 1 year ago

Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market

Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates

Aug 7, 2023, 4:05 PM EDT - 2 years ago

Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates

Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure

Jul 25, 2023, 9:25 AM EDT - 2 years ago

Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure

The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market

Jul 18, 2023, 9:00 AM EDT - 2 years ago

The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market

Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That

Jul 14, 2023, 9:00 AM EDT - 2 years ago

Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That

Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors

Jun 27, 2023, 8:00 AM EDT - 2 years ago

Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism

Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones

Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates

May 15, 2023, 4:30 PM EDT - 2 years ago

Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates

DDavidson777
DDavidson777 Jun. 16 at 10:32 PM
$WINT just a matter of time folks… 📈📈📈💚 Dont miss out on another banger… Crazy calls in past months or so and nearly another $1,000,000 locked in. Follow for more
0 · Reply
WSSHARKS
WSSHARKS Jun. 16 at 9:04 PM
$WINT If good news can't lift it, imagine what no news or bad news will do — straight to the incinerator
0 · Reply
Joe_088
Joe_088 Jun. 16 at 8:09 PM
$WINT
0 · Reply
abimbolajosh
abimbolajosh Jun. 16 at 7:09 PM
$WINT you are a pumper lol You’ve got to prove it
1 · Reply
kunnskap
kunnskap Jun. 16 at 7:03 PM
$WINT
0 · Reply
kunnskap
kunnskap Jun. 16 at 7:00 PM
$WINT
0 · Reply
Joe_088
Joe_088 Jun. 16 at 6:57 PM
$WINT ah or before close🌋
0 · Reply
GravyTrain1
GravyTrain1 Jun. 16 at 6:53 PM
$WINT what is this bs!
0 · Reply
GravyTrain1
GravyTrain1 Jun. 16 at 6:41 PM
$WINT
0 · Reply
Luke83
Luke83 Jun. 16 at 6:39 PM
$FOXO $BPT $WINT $MULN on watch
0 · Reply
Joe_088
Joe_088 Jun. 16 at 6:30 PM
$WINT it will explode patience many catalyst coming at any time
0 · Reply
raffallv
raffallv Jun. 16 at 6:25 PM
I have a good feelings about $WINT
0 · Reply
raffallv
raffallv Jun. 16 at 6:22 PM
$WINT can it brake 1.00?
0 · Reply
Quackstocks
Quackstocks Jun. 16 at 6:00 PM
$WINT
0 · Reply
Luke83
Luke83 Jun. 16 at 5:35 PM
$WINT
0 · Reply
Joe_088
Joe_088 Jun. 16 at 5:33 PM
$WINT has received a non-binding letter of intent to purchase its preclinical oncology aPKCi inhibitor platform for $7.0 million dollars up front in cash or freely tradable stock and up to $130 million in milestone payments and high, single digit royalties up to $1.5 billion.⏰⏰
0 · Reply
WSSHARKS
WSSHARKS Jun. 16 at 5:07 PM
$WINT Polishing a turd doesn’t make it gold. WINT is still a burning pile of trash
1 · Reply
Jobilly
Jobilly Jun. 16 at 5:06 PM
$WINT
0 · Reply
Joe_088
Joe_088 Jun. 16 at 5:03 PM
$WINT
0 · Reply
Bazzzigar
Bazzzigar Jun. 16 at 4:11 PM
$WINT
0 · Reply
Jobilly
Jobilly Jun. 16 at 4:06 PM
$WINT To all the shorts.. How's that dictate..>>
0 · Reply
Surfacetite_
Surfacetite_ Jun. 16 at 4:03 PM
$WINT lot of 100 prints. Games MMs playing. Let er rip!
0 · Reply